DDInter1555 DDInter1082
The 3-cyclopentyl ether of ethinyl estradiol.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Quinestrol {u} (Compound) resembles {v} (Compound) Mestranol
Quinestrol {u} (Compound) resembles {v} (Compound) Estramustine
Quinestrol {u} (Compound) binds {v} (Gene) ESR1
Quinestrol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Quinestrol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Quinestrol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Quinestrol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pramlintide
Quinestrol {u} may lead to a major life threatening interaction when taken with {v} Tranexamic acid
Quinestrol {u} may lead to a major life threatening interaction when taken with {v} Carfilzomib
Quinestrol (Compound) resembles Mestranol (Compound)
Quinestrol (Compound) resembles Estramustine (Compound)
Quinestrol (Compound) binds ESR1 (Gene)
Quinestrol may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Quinestrol may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Quinestrol may lead to a major life threatening interaction when taken with Tranexamic acid
Quinestrol may lead to a major life threatening interaction when taken with Carfilzomib